The 8 most recent market catalysts affecting $XNCR, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 11, 2026
Corporate Catalyst
Bullish
Impact 55
Barclays Maintains Overweight on Xencor, Raises Price Target to $35
Barclays analyst Etzer Darout maintained an 'Overweight' rating on Xencor and raised the price target from $27 to $35. This action signals a strengthened positive outlook from a re…
Sep 1, 2026
Corporate Catalyst
Bullish
Impact 55
Raymond James Maintains Strong Buy on Xencor, Raises Price Target to $46
Raymond James analyst Sean McCutcheon has maintained a 'Strong Buy' rating on Xencor (XNCR) and raised the price target from $40 to $46. This action signals increased confidence fr…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 55
RBC Capital Maintains Outperform on Xencor, Raises Price Target to $20
RBC Capital's analyst Leonid Timashev has raised the price target for Xencor (XNCR) from $19 to $20 while maintaining an Outperform rating. This action reflects a slightly improved…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 55
Wedbush Maintains Outperform on Xencor, Raises Price Target to $30
Wedbush analyst David Nierengarten has maintained an 'Outperform' rating on Xencor and raised the price target from $26 to $30. This action signals increased confidence in Xencor's…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 55
Cantor Fitzgerald Maintains Overweight on Xencor, Raises Price Target to $44
Cantor Fitzgerald analyst Steve Seedhouse has maintained an 'Overweight' rating on Xencor (XNCR) and raised the price target from $43 to $44. This action signals continued confiden…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 92
Xencor Q2 EPS $(0.29) Beats $(0.79) Estimate, Sales $51.200M Beat $18.922M Estimate
Xencor announced its Q2 financial results, reporting a loss per share of $(0.29) which significantly beat the analyst estimate of $(0.79). Additionally, the company's sales of $51.…
Jul 29, 2026
Corporate Catalyst
Bearish
Impact 85
Xencor Announces $105M Settlement From Alexion Over US Ultomiris Royalties In Two $52.5M Payments; Ends US Royalties, Extends Operating Runway Through 2028
This settlement is a major positive for Xencor, providing $105 million in non-dilutive capital, which significantly extends its operating runway through 2028. This reduces immediat…
Jul 17, 2026
Corporate Catalyst
Neutral
Impact 65
Xencor Announces Phase 1 Study Results For XmAb819 Antibody Accepted For Proffered Paper Oral Presentation At European Society of Medical Oncology October 23-27
Xencor's 8-K filing announces the acceptance of Phase 1 results for its XmAb819 antibody for an oral presentation at the prestigious ESMO conference. This is a positive development…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.